Patent US4288433A successfully refreshed from Google Patents.
US4288433A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cosmetic compositions having a slimming action
Assignee: L'Oréal SA
•
Filing: 1979-09-24
•
Granted: 1981-09-08
•
Expires: 1999-09-24
Abstract
Abstract The invention provides compositions which have a slimming and anti-cellulitis action when applied to the body, topically with massage or using trans-cutaneous electrophoresis. The compositions contain, in combination, a thioether and a xanthine derivative.
Inventors
- 👤 Constantin Koulbanis
- 👤 Claude Bouillon
- 👤 Patrick Darmenton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 13:48
CPC Classifications
A; A61; A61Q; A61Q19/00; A61Q19/06; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/695; A61K36/00; A61K36/18; A61K36/185; A61K36/23; A61K38/00; A61K38/16; A61K38/43; A61K38/46; A61K38/47; A61K8/00; A61K8/18; A61K8/30; A61K8/40; A61K8/44; A61K8/447; A61K8/49; A61K8/494; A61K8/4953; A61K8/4986; A61K8/58; A61K8/585; A61K8/64; A61K8/66; A61K8/96; A61K8/97; A61K8/9783; A61K8/9789; A61P; A61P3/00; A61P3/04; C; C12; C12Y; C12Y302/00; C12Y302/01; C12Y302/01035
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
142 words
A method for the treatment of cellulitis which comprises massaging the part of the body to be treated with a therapeutically effective amount of a composition containing in a suitable vehicle: (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR2## in which each of R 1 and R 3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R 1 and R 3 do not simultaneously represent a hydrogen atom and R 2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
Claim 2
Independent Claim
142 words
A method for the treatment of cellulitis which comprises massaging the part of the body to be treated with a therapeutically effective amount of a composition containing in a suitable vehicle: (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR2## in which each of R 1 and R 3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R 1 and R 3 do not simultaneously represent a hydrogen atom and R 2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
Claim 3
Dependent Claim
20 words
The process of claim 1 in which said treatment is carried out once a day for 2 to 8 weeks.
Claim 4
Dependent Claim
27 words
The process of claim 1 in which said xanthine derivative is selected from the group consisting of theophylline, theobromine, caffeine, 3-butyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 1,3,7-triethylxanthine, 3-cyclohexyl-1-ethylxanthine, 3-ethyl-1-propynylxanthine and 3-ethyl-1-pentylxanthine.
Claim 5
Independent Claim
138 words
A method for the treatment of cellulitis which comprises treating the skin, using the transcutaneous electrophoresis technique, with a therapeutically effective amount of an aqueous solution containing: (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR3## in which each of R 1 and R 3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R 1 and R 3 do not simultaneously represent a hydrogen atom and R 2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
Claim 6
Independent Claim
138 words
A method for the treatment of cellulitis which comprises treating the skin, using the transcutaneous electrophoresis technique, with a therapeutically effective amount of an aqueous solution containing: (1) 0.1 to 1.5% by weight of a thioether selected from the group consisting of: S-carboxymethylcysteine, S-carboxymethylhomocysteine, thiolane-3,4-diol, thiolane-3,4-diol S-oxide, thiolane-3,4-diol S-dioxide and the malate, salicylate, nicotinate, tartrate or 5-amino-3-thiahexanedioate of 2-benzylthioethylamine, and (2) 0.1 to 2% by weight of a xanthine derivative having the formula: ##STR3## in which each of R 1 and R 3 independently represents a hydrogen atom, a linear or branched alkyl radical having 1 to 5 carbon atoms, an allyl radical, a propynyl radical or a cyclohexyl radical with the proviso that R 1 and R 3 do not simultaneously represent a hydrogen atom and R 2 represents hydrogen, a methyl, ethyl, hydroxymethyl or hydroxyethyl radical.
Claim 7
Dependent Claim
25 words
The process of claim 4 in which said treatment is carried out for 4 to 8 weeks at a rate of three ionisations per week.
Claim 8
Dependent Claim
27 words
The process of claim 4 in which said xanthine derivative is selected from the group consisting of theophylline, theobromine, caffeine, 3-butyl-1-methylxanthine, 3-isobutyl-1-methylxanthine, 1,3,7-triethylxanthine, 3-cyclohexyl-1-ethylxanthine, 3-ethyl-1-propynylxanthine and 3-ethyl-1-pentylxanthine.
References Cited (Backward Citations)
US3849576A
Cited
US3879560A
Cited
US3976781A
Cited
US4002671A
Cited
US3671643A
Cited
USRE29256E
Cited
US3950532A
Cited
US3978213A
Cited
US3919226A
Cited
US4086347A
Cited
US4123534A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-07 | 1985-03-09 | 1985-09-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-07 | 1989-03-09 | 1989-09-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-07 | 1993-03-09 | 1993-09-08 | $7700.00 | Window Closed / Lapsed |